S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Avenue Therapeutics (ATXI) Stock Forecast, Price & News

-0.02 (-6.43%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
89,760 shs
Average Volume
3.35 million shs
Market Capitalization
$6.32 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Avenue Therapeutics logo

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.05 per share


Net Income
$-3.73 million
Pretax Margin




Free Float
Market Cap
$6.32 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 82,800 shares, an increase of 212.5% from the April 15th total of 26,500 shares. Based on an average daily volume of 4,880,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.8% of the company's shares are sold short.
View Avenue Therapeutics' Short Interest

When is Avenue Therapeutics' next earnings date?

Avenue Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Avenue Therapeutics

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced its earnings results on Sunday, November, 14th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05).
View Avenue Therapeutics' earnings history

Who are Avenue Therapeutics' key executives?
Avenue Therapeutics' management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 67)
  • Dr. Xiaoqin Lu M.D., Consultant (Age 47, Pay $699.33k)
  • David Jin, Interim Principal Exec. Officer
  • Dr. Scott A. Reines M.D., Ph.D., Interim Chief Medical Officer (Age 75)
What other stocks do shareholders of Avenue Therapeutics own?
When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

Who are Avenue Therapeutics' major shareholders?

Avenue Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.27%). Company insiders that own Avenue Therapeutics stock include Joseph Walter Vazzano and Neil Herskowitz.
View institutional ownership trends for Avenue Therapeutics

Which institutional investors are buying Avenue Therapeutics stock?

ATXI stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Avenue Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $0.29.

How much money does Avenue Therapeutics make?

Avenue Therapeutics has a market capitalization of $6.32 million.

How many employees does Avenue Therapeutics have?

Avenue Therapeutics employs 4 workers across the globe.

What is Avenue Therapeutics' official website?

The official website for Avenue Therapeutics is www.avenuetx.com.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The company can be reached via phone at (781) 652-4500 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.